Navigation Links
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
Date:4/23/2009

tiated mature cells, such as adult skin cells, to become pluripotent or stem-cell like and do not rely on the use of stem cells derived from embryos. Because iPS cells can differentiate into any cell type, iPS cells are considered of great importance to medicine because they can be used to model human diseases, discover and test drug candidates and develop personalized cell therapies. Previously, iPS cell generation required the delivery of genetic material through viruses or plasmids, which carry risks from insertion and are time-consuming, inefficient methods. Now, in collaboration with Dr. Ding, Fate Therapeutics and Stemgent have developed small molecules and proteins for the safe and efficient creation of high quality iPS cells that can reproducibly differentiate into essential cell types for drug discovery and development.

"Catalyst's technology - creating and differentiating iPS cells into distinct cell types - will uncover the essential epigenetic and gene expression profiles associated with the derivation of specific cell lineages," said Mr. Grayson. "These same technologies will prove critical in our discovery and development of conventional pharmaceuticals to guide cell fate for therapeutic benefit."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating stem cell biology to develop therapeutics based on modulating cell fate and to enable a new drug discovery paradigm with the Company's proprietary induced-pluripotent stem (iPS) cell technology. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic reconstitution. Fate Therapeutics is a private biotech company headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.

About Stemgent, Inc.

'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , AIX-EN-PROVENCE, France, ... received 510K Clearance from the FDA for its Aixplorer(TM) ultrasound ... in the United States. Aixplorer is the only commercially ... based upon interaction between conventional longitudinal waves and shear waves ...
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., a ... clinical trial to evaluate the safety, tolerability, pharmacokinetics, and ... Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer ... diseases. , , The Phase Ib ...
... ... An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases , ... New York, NY/Rockville, MD (Vocus) August ... National Multiple Sclerosis Society,s subsidiary devoted to bridging the gap between research and drug ...
Cached Biology Technology:SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 2Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 4
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... CITY, Aug. 31, 2009 Researchers at Huntsman Cancer Institute ... on Ewing,s sarcoma, an often deadly bone cancer that typically ... with poor outcomes have tumors with high levels of a ... chemotherapy. The research is published online today in the journal ...
... its usefulness in counting copies of duplicated genome sequences and ... study to be published Aug. 30 in Nature Genetics ... differ from one person to the next. The researchers ... Search Tool. The study is titled, "Personalized Copy Number and ...
... on the neural mechanisms involved in social behavior, neuroscientists ... the brain structure responsible for our sense of personal ... 30 issue of the journal Nature Neuroscience , ... social distance is an issue. The structure, the ...
Cached Biology News:New hope for deadly childhood bone cancer 2Counting duplicated genome segments now possible 2Counting duplicated genome segments now possible 3Caltech neuroscientists find brain region responsible for our sense of personal space 2Caltech neuroscientists find brain region responsible for our sense of personal space 3Caltech neuroscientists find brain region responsible for our sense of personal space 4
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), ... that is cleaved by living cells to ... process requires active mitochondria, and even freshly ... of MTT. Reagent A is a component ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: